Verified by AISci
Public source attached
Source status for this paper in the current AISci reviewed snapshot.
- Primary source
- ClinicalTrials.gov
- Correction status
- none
- Evidence coverage
- 1 sources / 1 publishers
- Last metadata check
- Jul 19, 2026
clinical trialBiotech
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors (NCT07287917)
Source-permitted summary
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | Phase: PHASE1 | Conditions: Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
SourceClinicalTrials.govAI Reading Notes
Core signal
Structured notes generated from source-linked AISci metadata. Treat them as a reading aid, not a substitute for the paper.
- Core signal
- Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | Phase: PHASE1 | Conditions: Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
- Field context
- Protein and Drug Design
- People and labs
- Not stated in the reviewed source.
- Why it matters
- Clinical trial registry updates are translation signals, not commercialization claims by themselves.
- Limits to check
- ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.
Research Workflow
Research Workflow
Recommended next steps for turning this signal into research action.
- Read original source
- Check DOI/OpenAlex
- Open relationship graph
- Review people and labs: Not stated in the reviewed source.
- Open linked event for AISci context
- Prepare journal-club PPT: AISci action coming next
- Plan replication checks: AISci action coming next
Publication facts
- Type
- clinical trialSourceClinicalTrials.gov
- Date
- Jul 15, 2026SourceClinicalTrials.gov
- Venue
- ClinicalTrials.govSourceClinicalTrials.gov
- Open access
- openSourceClinicalTrials.gov
External IDs
Author order
No reviewed author edge is attached to this output.
Organizations
No source-confirmed author affiliation is attached.
Related events
Topics
Relationship evidence
Protein and Drug Design
Controlled AISci Stage A topic for Protein and Drug Design.
Aminex Therapeutics, Inc.
Organization linked by public source evidence.
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Clinical/translation signal: Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Timeline
- clinical trialStudy of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors